î
îŒ
î
IDEAYA Biosciences Inc
IDYA35.200USD
-0.480-1.35%
çµå€Â 12/26, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
3.09Bæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± IDEAYA Biosciences Inc äŒæ¥å
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
IDEAYA Biosciences Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãIDYA
äŒç€ŸåIDEAYA Biosciences Inc
äžå Žæ¥May 23, 2019
æé«çµå¶è²¬ä»»è
ãCEOãHata (Yujiro S)
åŸæ¥å¡æ°131
蚌åžçš®é¡Ordinary Share
決ç®ææ«May 23
æ¬ç€Ÿæåšå°7000 Shoreline Ct, Suite 350
éœåžSOUTH SAN FRANCISCO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·94080
é»è©±çªå·16504436209
ãŠã§ããµã€ãhttps://www.ideayabio.com/
äŒæ¥ã³ãŒãIDYA
äžå Žæ¥May 23, 2019
æé«çµå¶è²¬ä»»è
ãCEOãHata (Yujiro S)
IDEAYA Biosciences Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
åçå èš³
é貚: USDæŽæ°æå»: Mon, Oct 6
é貚: USDæŽæ°æå»: Mon, Oct 6
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
7.00M
100.00%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
æ ªäž»
æŽæ°æå»: Sun, Nov 30
æŽæ°æå»: Sun, Nov 30
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.59%
ä»ã®
57.38%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Fidelity Management & Research Company LLC
15.00%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.33%
BlackRock Institutional Trust Company, N.A.
7.23%
The Vanguard Group, Inc.
5.59%
ä»ã®
57.38%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
48.76%
Investment Advisor/Hedge Fund
32.44%
Hedge Fund
19.91%
Research Firm
3.93%
Venture Capital
3.62%
Pension Fund
1.00%
Individual Investor
0.90%
Bank and Trust
0.43%
Insurance Company
0.07%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Fidelity Management & Research Company LLC
13.14M
14.99%
+7.07K
+0.05%
Jun 30, 2025
Capital Research Global Investors
6.55M
7.48%
+3.82M
+139.59%
Jun 30, 2025
Janus Henderson Investors
6.21M
7.08%
-195.54K
-3.05%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.67M
7.61%
-480.56K
-6.72%
Jun 30, 2025
The Vanguard Group, Inc.
4.92M
5.62%
-152.94K
-3.01%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
4.63M
5.28%
-140.66K
-2.95%
Jun 30, 2025
Point72 Asset Management, L.P.
5.03M
5.74%
+4.89M
+3488.42%
Jun 30, 2025
Baker Bros. Advisors LP
2.12M
2.42%
+1.06M
+99.48%
Jun 30, 2025
State Street Investment Management (US)
3.39M
3.86%
-60.44K
-1.75%
Jun 30, 2025
Adage Capital Management, L.P.
1.24M
1.41%
+50.00K
+4.21%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Tema Oncology ETF
3.49%
ALPS Medical Breakthroughs ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
0.83%
State Street SPDR S&P Biotech ETF
0.72%
First Trust Innovation Leaders ETF
0.7%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
ProShares Ultra Nasdaq Biotechnology
0.38%
Avantis US Small Cap Equity ETF
0.29%
Invesco Nasdaq Biotechnology ETF
0.27%
詳现ãèŠã
Tema Oncology ETF
æ¯ç3.49%
ALPS Medical Breakthroughs ETF
æ¯ç1.16%
Virtus LifeSci Biotech Clinical Trials ETF
æ¯ç0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
æ¯ç0.83%
State Street SPDR S&P Biotech ETF
æ¯ç0.72%
First Trust Innovation Leaders ETF
æ¯ç0.7%
Direxion Daily S&P Biotech Bull 3X Shares
æ¯ç0.45%
ProShares Ultra Nasdaq Biotechnology
æ¯ç0.38%
Avantis US Small Cap Equity ETF
æ¯ç0.29%
Invesco Nasdaq Biotechnology ETF
æ¯ç0.27%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
IDEAYA Biosciences Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îIDEAYA Biosciences Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Fidelity Management & Research Company LLCã¯13.14Mæ ªãä¿æããŠãããããã¯å šäœã®14.99%ã«çžåœããŸãã
Capital Research Global Investorsã¯6.55Mæ ªãä¿æããŠãããããã¯å šäœã®7.48%ã«çžåœããŸãã
Janus Henderson Investorsã¯6.21Mæ ªãä¿æããŠãããããã¯å šäœã®7.08%ã«çžåœããŸãã
BlackRock Institutional Trust Company, N.A.ã¯6.67Mæ ªãä¿æããŠãããããã¯å šäœã®7.61%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯4.92Mæ ªãä¿æããŠãããããã¯å šäœã®5.62%ã«çžåœããŸãã
Fidelity Management & Research Company LLCã¯13.14Mæ ªãä¿æããŠãããããã¯å šäœã®14.99%ã«çžåœããŸãã
Capital Research Global Investorsã¯6.55Mæ ªãä¿æããŠãããããã¯å šäœã®7.48%ã«çžåœããŸãã
Janus Henderson Investorsã¯6.21Mæ ªãä¿æããŠãããããã¯å šäœã®7.08%ã«çžåœããŸãã
BlackRock Institutional Trust Company, N.A.ã¯6.67Mæ ªãä¿æããŠãããããã¯å šäœã®7.61%ã«çžåœããŸãã
The Vanguard Group, Inc.ã¯4.92Mæ ªãä¿æããŠãããããã¯å šäœã®5.62%ã«çžåœããŸãã
IDEAYA Biosciences Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îIDEAYA Biosciences Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Fidelity Management & Research Company LLC
Capital Research Global Investors
Janus Henderson Investors
Fidelity Management & Research Company LLC
Capital Research Global Investors
Janus Henderson Investors
IDEAYA Biosciences IncïŒIDYAïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãIDEAYA Biosciences Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯460瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ105.73Mã§ãå
šäœã®120.62%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯4.57%å¢å ããŠããŸãã
IDEAYA Biosciences Incã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2024ã«ãããŠãWRNéšéãIDEAYA Biosciences Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯7.00Mã§ãå
šåçã®--%ãå ããŠããŸãã
